Business Context and Reporting Period
Chemomab Therapeutics Ltd., a foreign private issuer based in Tel-Aviv, Israel, filed this Form 6-K for the month of July 2025. The filing discloses the execution of a Sales Agreement on July 25, 2025, with LifeSci Capital, LLC to facilitate an "at the market" (ATM) offering of American Depositary Shares (ADSs).
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new securities offering.
- Maximum Offering Size: Up to $7,258,687 in aggregate offering price.
- Security Type: American Depositary Shares (ADSs), where each ADS represents 20 ordinary shares.
- Agent Commission: 3.0% of gross proceeds from sales.
- Registration Basis: Issued pursuant to a shelf registration statement on Form F-3 (File No. 333-275002).
Material Changes
The primary material change disclosed is the establishment of the ATM Offering facility. This agreement allows the Company to sell shares from time to time based on market conditions. The filing explicitly states that the Company is not obligated to make any sales, and no assurance is given regarding the price, number of shares, or timing of any future sales.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of specific business risks beyond the standard securities law disclaimers. Key contingencies include:
- Sale Uncertainty: The Company may choose not to sell any shares under the agreement.
- Termination: The Sales Agreement may be terminated by either party as set forth in the agreement terms.
- Market Dependency: Sales will be made at prevailing market prices, subject to instructions from the Company regarding price, time, or size limits.
Investor Verification Checklist
- Verify the current market price of Chemomab Therapeutics ADSs to assess potential dilution impact if the full $7,258,687 is raised.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific termination clauses and conditions.
- Check subsequent filings to determine if any shares have actually been sold under this ATM facility.
- Confirm the Company's current cash position in its most recent Form 20-F to understand the necessity of this capital raise.